Concept Number |
Draft Concepts
*These concepts are under consideration and have not yet been approved.
|
DC-001 |
Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects |
| DC-002 |
A Phase I Double-Blind, Placebo-Controlled Study to Confirm the Safety and Tolerability of Intravenous Peramivir in Healthy Asian Subjects |
| DC-003 |
Intravenous Peramivir vs Oral Oseltamivir for the Treatment of Hospitalized Influenza: A Phase II Randomized Double-Blind Study |
| DC-004 |
A Randomized Double Blind Phase IV Trial to Evaluate Safety and Tolerability of Long Term Influenza Prophylaxis with Inhaled Zanamivir or Oral Oseltamivir |
| DC-005 |
An Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous Zanamivir Administered Twice Daily for 5 days in Hospitalized Subjects with Confirmed H5N1 Influenza Infection |
| DC-006 |
A Randomized, Double-blind, Double-dummy, Parallel group, Active-comparator Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous Zanamivir Administered twice Daily for 5 days in Hospitalized Subjects with Confirmed Seasonal Influenza |
| DC-007 |
Host Genetic Susceptibility to Human Influenza A/H5N1 |
| DC-009 |
WHO Clinical Database with H5N1 Cases World-wide |
